返回 
加入收藏
替诺福韦联合干扰素α1b治疗慢性乙型肝炎的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 替诺福韦联合干扰素α1b治疗慢性乙型肝炎的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察替诺福韦联合干扰素α1b治疗慢性乙型肝炎（以下简称“乙肝”）的临床疗效与安全性。方法：96例慢性乙肝患者依据随机数字表法分为对照组、A观察组与B观察组，各32例。对照组患者给予恩替卡韦口服，每次0.5 mg，qd；A观察组患者给予替诺福韦口服，每次1片，qd；B观察组患者在A观察组基础上肌内注射干扰素α1b，每次50 μg，每周3次。3组疗程均为48周。比较3组患者的临床疗效、治疗前后血清肝功能指标、乙肝病毒脱氧核糖核酸（HBV-DNA）阴转率及不良反应发生情况。结果：B观察组患者的总有效率（84.38％）明显高于A观察组（62.60％）和对照组（37.50％），A观察组明显高于对照组，差异均有统计学意义（P＜0.05）。与治疗前比较，3组患者治疗后的血清天冬氨酸转氨酶、丙氨酸转氨酶、总胆红素水平均明显下降，且B观察组患者的各项指标均明显低于A观察组和对照组，差异均有统计学意义（P＜0.05），而A观察组和对照组之间比较，差异均无统计学意义（P＞0.05）。B观察组患者治疗12周和24周的HBV-DNA阴转率均明显高于同期A观察组和对照组，差异均有统计学意义（P＜0.05），而A观察组和对照组之间比较，差异均无统计学意义（P＞0.05）。3组患者均未见明显不良反应发生。结论：替诺福韦联合干扰素α1b治疗慢性乙肝的临床疗效显著，明显优于单用恩替卡韦和替诺福韦。 |
| ABSTRACT： | OBJECTIVE： To observe clinical efficacy and safety of individual antiviral therapy of tenofovir combined with interferon α1b for chronic hepatitis B （CHB）. METHODS： 96 CHB patients were randomly divided into control group， observation group A and observation group B， with 32 cases in each group. Control group was given entecavir orally， 0.5 mg， qd； observation group A was given tenofovir orally， 1 piece， qd； observation group B was additionally given interferon α1b， 50 μg， 3 times a week， on the basis of observation group A. The treatment course lasted for 48 weeks in 3 groups. Clinical efficacy of 3 groups was compared， and the changes of serum liver function indexes， HBV-DNA negative conversion rate and the occurrence of ADR were compared before and after treatment. RESULTS： The total effective rate of observation group B （84.38％） was significantly higher than that of observation group A （62.60％） and control group （37.50％）， and that of observation group A was significantly higher than control group， with statistical significance （P＜0.05）. Compared with before treatment， the serum levels of AST， ALT and TBIL were significantly decreased after treatment in 3 groups； the observation group B were significantly lower than those of observation group A and control group， with statistical significance （P＜0.05）； there was no statistical significance between observation group A and control group （P＞0.05）. The negative rate of HBV-DNA in observation group B were significantly higher than those in control group and observation group A after 12 and 24 weeks of treatment， with statistical significance （P＜0.05）； there was no statistical significance between observation group A and control group （P＞0.05）. No obvious ADR was found in 3 groups. CONCLUSIONS： Tenofovir combined with interferon α1b shows significant clinical efficacy for CHB， and is significantly better than that of entecavir and tenofovir alone. |
| 期刊： | 2016年第27卷第17期 |
| 作者： | 李献平，赵鸿霞，张勤俭，李丽芳，宁振海 |
| AUTHORS： | LI Xianping，ZHAO Hongxia，ZHANG Qinjian，LI Lifang，NING Zhenhai |
| 关键字： | 替诺福韦；干扰素α1b；恩替卡韦；慢性乙型肝炎 |
| KEYWORDS： | Tenofovir； Interferon α1b； Entecavir； Chronic hepatitis B |
| 阅读数： | 456 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
